Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.39 |
| ▸ | CRHBP | P24387 | 1/20 | 0.39 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 4/20 | 0.38 |
| ▸ | GLS | O94925 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28491930 | 0.85 | KDM4E (0.45) | KDM4EKMT2AALDH1A1MAPTADORA2A | |
| SCHEMBL17917631 | 0.85 | ALDH1A1 (0.48) | KDM4ENPC1KMT2AMEN1ALDH1A1 | |
| SCHEMBL22582787 | 0.81 | KMT2A (0.53) | KDM4EKMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL102723 | 0.81 | KMT2A (0.46) | KDM4ENPC1KMT2AALDH1A1MAPT | |
| SCHEMBL10049616 | 0.80 | ADORA2A (0.38) | KDM4ENPC1KMT2AMEN1ALDH1A1 | |
| SCHEMBL13184405 | 0.79 | KDM4E (0.47) | KDM4ENPC1KMT2AMEN1ALDH1A1 | |
| SCHEMBL21753564 | 0.78 | NPC1 (0.44) | KDM4ENPC1KMT2AMEN1ALDH1A1 | |
| SCHEMBL20874552 | 0.78 | GAA (0.51) | KDM4ENPC1KMT2AMEN1ALDH1A1 | |
| SCHEMBL1326752 | 0.78 | KDM4E (0.51) | KDM4ENPC1ALDH1A1MAPTADORA2A | |
| SCHEMBL26924428 | 0.78 | NPC1 (0.44) | KDM4ENPC1KMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240287093-A1 | HIGH ACTIVITY STING PROTEIN AGONIST | ADLAI NORTYE BIOPHARMA CO., LTD. (CN) | 2024-08-29 | — | — | US | disclosed |
| CN-111655682-B | High-activity STING protein agonist compound | 杭州阿诺生物医药科技有限公司 | 2024-05-31 | — | — | CN | disclosed |
| EP-3842437-B1 | HIGH ACTIVITY STING PROTEIN AGONIST | ADLAI NORTYE BIOPHARMA CO LTD (CN) | 2024-04-10 | — | — | EP | disclosed |
| CN-113354677-B | Acrylonitrile compound and preparation method and application thereof | 华中师范大学 | 2023-08-01 | — | — | CN | disclosed |
| CN-111386275-B | High activity STING protein agonists | 杭州阿诺生物医药科技有限公司 | 2023-03-10 | — | — | CN | disclosed |
| CN-112552314-B | Small-molecule anti-tumor compound of STING agonist and application thereof | 杭州阿诺生物医药科技有限公司 | 2022-03-04 | — | — | CN | disclosed |
| CN-113354677-A | Acrylonitrile compound and preparation method and application thereof | 华中师范大学 | 2021-09-07 | — | — | CN | disclosed |
| EP-3842437-A1 | HIGH ACTIVITY STING PROTEIN AGONIST | Adlai Nortye Biopharma Co., Ltd. (CN) | 2021-06-30 | — | — | EP | disclosed |
| EP-3842437-A1 | HIGH ACTIVITY STING PROTEIN AGONIST | Adlai Nortye Biopharma Co., Ltd. (CN) | 2021-06-30 | — | — | EP | disclosed |
| CN-112552314-A | Small-molecule anti-tumor compound of STING agonist and application thereof | 杭州阿诺生物医药科技有限公司 | 2021-03-26 | — | — | CN | disclosed |
| CN-108329263-B | 1, 8-naphthalimide amide compound and application thereof | 青岛科技大学 | 2020-12-15 | — | — | CN | disclosed |
| CN-111655682-A | High-activity STING protein agonist compound | 杭州阿诺生物医药科技有限公司 | 2020-09-11 | — | — | CN | disclosed |
| CN-111386275-A | High activity STING protein agonists | 杭州阿诺生物医药科技有限公司 | 2020-07-07 | — | — | CN | disclosed |
| WO-2020042995-A1 | HIGHLY ACTIVE STING PROTEIN AGONIST COMPOUND | 杭州阿诺生物医药科技有限公司 | 2020-03-05 | — | — | WO | disclosed |
| WO-2020038387-A1 | HIGH ACTIVITY STING PROTEIN AGONIST | 杭州阿诺生物医药科技有限公司 | 2020-02-27 | — | — | WO | disclosed |
| WO-2020038387-A1 | HIGH ACTIVITY STING PROTEIN AGONIST | 杭州阿诺生物医药科技有限公司 | 2020-02-27 | — | — | WO | disclosed |
| CN-108329263-A | A kind of 1,8- naphthalimides amides compound and application thereof | 青岛科技大学 | 2018-07-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287093-A1 | HIGH ACTIVITY STING PROTEIN AGONIST | STING1, IRF3, MAVS | KDM4E 3778/4885NPC1 541/4885KMT2A 4153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.